267 related articles for article (PubMed ID: 28284718)
21. Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells.
Zgheib A; Pelletier-Bonnier É; Levros LC; Annabi B
Cytokine; 2013 Aug; 63(2):187-93. PubMed ID: 23688618
[TBL] [Abstract][Full Text] [Related]
22. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.
Kim BH; Min YS; Choi JS; Baeg GH; Kim YS; Shin JW; Kim TY; Ye SK
Exp Mol Med; 2011 May; 43(5):313-21. PubMed ID: 21499010
[TBL] [Abstract][Full Text] [Related]
23. Jak3 deficiency blocks innate lymphoid cell development.
Robinette ML; Cella M; Telliez JB; Ulland TK; Barrow AD; Capuder K; Gilfillan S; Lin LL; Notarangelo LD; Colonna M
Mucosal Immunol; 2018 Jan; 11(1):50-60. PubMed ID: 28513593
[TBL] [Abstract][Full Text] [Related]
24. Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib.
Hekmatnejad M; Conwell S; Lok SM; Kutach A; Shaw D; Fang E; Swinney DC
Arch Biochem Biophys; 2016 Dec; 612():22-34. PubMed ID: 27555492
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.
Lee S; Park HY; Kang SY; Kim SJ; Hwang J; Lee S; Kwak SH; Park KS; Yoo HY; Kim WS; Kim JI; Ko YH
Oncotarget; 2015 Jul; 6(19):17764-76. PubMed ID: 25980440
[TBL] [Abstract][Full Text] [Related]
26. Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan.
Kimura H; Karube K; Ito Y; Hirano K; Suzuki M; Iwata S; Seto M
Leuk Lymphoma; 2014 Apr; 55(4):962-3. PubMed ID: 23808814
[No Abstract] [Full Text] [Related]
27. JAK3-STAT pathway blocking benefits in experimental lupus nephritis.
Ripoll È; de Ramon L; Draibe Bordignon J; Merino A; Bolaños N; Goma M; Cruzado JM; Grinyó JM; Torras J
Arthritis Res Ther; 2016 Jun; 18(1):134. PubMed ID: 27278657
[TBL] [Abstract][Full Text] [Related]
28. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Song TL; Nairismägi ML; Laurensia Y; Lim JQ; Tan J; Li ZM; Pang WL; Kizhakeyil A; Wijaya GC; Huang DC; Nagarajan S; Chia BK; Cheah D; Liu YH; Zhang F; Rao HL; Tang T; Wong EK; Bei JX; Iqbal J; Grigoropoulos NF; Ng SB; Chng WJ; Teh BT; Tan SY; Verma NK; Fan H; Lim ST; Ong CK
Blood; 2018 Sep; 132(11):1146-1158. PubMed ID: 30054295
[TBL] [Abstract][Full Text] [Related]
30. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group.
Kim TM; Lee SY; Jeon YK; Ryoo BY; Cho GJ; Hong YS; Kim HJ; Kim SY; Kim CS; Kim S; Kim JS; Sohn SK; Song HH; Lee JL; Kang YK; Yim CY; Lee WS; Yuh YJ; Kim CW; Heo DS;
Ann Oncol; 2008 Aug; 19(8):1477-1484. PubMed ID: 18385201
[TBL] [Abstract][Full Text] [Related]
31. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
[TBL] [Abstract][Full Text] [Related]
32. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA
Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
[TBL] [Abstract][Full Text] [Related]
33. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
34. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
35. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
de Vicente J; Lemoine R; Bartlett M; Hermann JC; Hekmat-Nejad M; Henningsen R; Jin S; Kuglstatter A; Li H; Lovey AJ; Menke J; Niu L; Patel V; Petersen A; Setti L; Shao A; Tivitmahaisoon P; Vu MD; Soth M
Bioorg Med Chem Lett; 2014 Nov; 24(21):4969-75. PubMed ID: 25262541
[TBL] [Abstract][Full Text] [Related]
36. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
[TBL] [Abstract][Full Text] [Related]
38. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity.
Kim BH; Oh SR; Yin CH; Lee S; Kim EA; Kim MS; Sandoval C; Jayabose S; Bach EA; Lee HK; Baeg GH
Br J Haematol; 2010 Jan; 148(1):132-43. PubMed ID: 19793252
[TBL] [Abstract][Full Text] [Related]
39. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
40. PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Xu H; Jesson MI; Seneviratne UI; Lin TH; Sharif MN; Xue L; Nguyen C; Everley RA; Trujillo JI; Johnson DS; Point GR; Thorarensen A; Kilty I; Telliez JB
ACS Chem Biol; 2019 Jun; 14(6):1235-1242. PubMed ID: 31082193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
